好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Portable MRI in the Hospital Setting: A Six-year Evaluation of Safety, Tolerability, and Utility
Neuro Trauma and Critical Care
P6 - Poster Session 6 (5:00 PM-6:00 PM)
19-007

To review portable MRI utilization at a single tertiary care center over six years.

Limited access to conventional MRI poses a challenge in both acute care settings where patients are often critically ill, and in resource-constrained environments. Portable MRI provides bedside neuroimaging that addresses these barriers. We report a six-year experience of pMRI deployment across multiple hospital settings at an urban tertiary care center, focusing on feasibility, safety, and clinical utility.
Between July 2018 and December 2024, pMRI scans were performed using a 0.064 T low-field unit. Scans were obtained in emergency department (ED), intensive care unit (ICU), or operating room. Feasibility was assessed by scan completion rates, reasons for non-completion, and patient tolerability. Safety was assessed by adverse event monitoring.
Of 1,173 attempted pMRI scans, 1,060 (90.4%) were successfully completed. No serious adverse events occurred. Incomplete scans (n=113) were most commonly due to patient requests to stop (n=77, 68.1%), either due to physical discomfort (n=27, 23.9%), claustrophobia (n=23, 21.2%), or an unspecified request (n=27, 23.9%). Additional scans were terminated due to physical incompatibility with the device (n=10, 8.9%), machine failure (n=8, 7.1%), and clinical instability (n=7, 6.2%). Scans were performed across a broad range of settings, most commonly the Neuroscience ICU (n=523, 48.7%), ED (n=346, 32.2%) and Medical ICU (n=58, 5.4%). Presentations included acute ischemic stroke or stroke code (n=371, 32.4%), intracerebral hemorrhage (n=131, 11.4%), white matter hyperintensity screening (n=158, 13.8%), tumor (n=94, 8.2%), subarachnoid hemorrhage (n=52, 4.6%), and cardiac arrest (n=29, 2.5%). 
Portable MRI was safe, well-tolerated, and feasible across acute care settings. Over six years and more than a thousand scans, no serious adverse events occurred, and the majority of patients, including critically ill individuals, successfully completed imaging. These findings highlight pMRI as a reliable bedside tool that expands neuroimaging access and complements conventional MRI.
Authors/Disclosures
Ian P. Johnson
PRESENTER 		Mr. Johnson has nothing to disclose.
Hailey Brigger Ms. Brigger has nothing to disclose.
Annabelle Shanks, BS Ms. Shanks has nothing to disclose.
Steph Maynez Ms. Maynez has nothing to disclose.
Alison Champagne Mrs. Champagne has nothing to disclose.
Gordon Sze Gordon Sze has nothing to disclose.
Emily J. Gilmore, MD (Yale University School of Medicine) Dr. Gilmore has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for carpl.ai. Dr. Gilmore has received personal compensation in the range of $0-$499 for serving as a Consultant for AAN. Dr. Gilmore has received research support from NIH.
Rachel Beekman, MD (Yale New Haven Medical Center) Dr. Beekman has nothing to disclose.
Adam De Havenon, MD, FAAN (Yale University) Dr. De Havenon has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novo Nordisk. Dr. De Havenon has or had stock in Certus.Dr. De Havenon has or had stock in TitinKM. The institution of Dr. De Havenon has received research support from NIH/NINDS. Dr. De Havenon has received publishing royalties from a publication relating to health care.
Kevin N. Sheth, MD, FAAN (Yale UniversityDivision of Neuro and Critical Care) Dr. Sheth has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ceribell. Dr. Sheth has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Zoll. Dr. Sheth has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NControl. Dr. Sheth has received stock or an ownership interest from Astrocyte. Dr. Sheth has received stock or an ownership interest from Alva. The institution of Dr. Sheth has received research support from Biogen. The institution of Dr. Sheth has received research support from Novartis. The institution of Dr. Sheth has received research support from Bard. The institution of Dr. Sheth has received research support from Hyperfine. Dr. Sheth has received intellectual property interests from a discovery or technology relating to health care.